Literature DB >> 18354030

Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury.

Mauro Abbate1, Carla Zoja, Daniela Corna, Daniela Rottoli, Cristina Zanchi, Nadia Azzollini, Susanna Tomasoni, Silvia Berlingeri, Marina Noris, Marina Morigi, Giuseppe Remuzzi.   

Abstract

Intrarenal complement activation leads to chronic tubulointerstitial injury in animal models of proteinuric nephropathies, making this process a potential target for therapy. This study investigated whether a C3-mediated pathway promotes renal injury in the protein overload model and whether the abnormal exposure of proximal tubular cells to filtered complement could trigger the resulting inflammatory response. Mice with C3 deficiency were protected to a significant degree against the protein overload-induced interstitial inflammatory response and tissue damage, and they had less severe podocyte injury and less proteinuria. When the same injury was induced in wild-type (WT) mice, antiproteinuric treatment with the angiotensin-converting enzyme inhibitor lisinopril reduced the amount of plasma protein filtered, decreased the accumulation of C3 by proximal tubular cells, and protected against interstitial inflammation and damage. For determination of the injurious role of plasma-derived C3, as opposed to tubular cell-derived C3, C3-deficient kidneys were transplanted into WT mice. Protein overload led to the development of glomerular injury, accumulation of C3 in podocytes and proximal tubules, and tubulointerstitial changes. Conversely, when WT kidneys were transplanted into C3-deficient mice, protein overload led to a more mild disease and abnormal C3 deposition was not observed. These data suggest that the presence of C3 increases the glomerular filtration barrier's susceptibility to injury, ultrafiltered C3 contributes more to tubulointerstitial damage induced by protein overload than locally synthesized C3, and local C3 synthesis is irrelevant to the development of proteinuria. It is speculated that therapies targeting complement combined with interventions to minimize proteinuria would more effectively prevent the progression of renal disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18354030      PMCID: PMC2396931          DOI: 10.1681/ASN.2007060686

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  57 in total

1.  Transforming growth factor-beta1 is up-regulated by podocytes in response to excess intraglomerular passage of proteins: a central pathway in progressive glomerulosclerosis.

Authors:  Mauro Abbate; Carla Zoja; Marina Morigi; Daniela Rottoli; Stefania Angioletti; Susanna Tomasoni; Cristina Zanchi; Lorena Longaretti; Roberta Donadelli; Giuseppe Remuzzi
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

Review 2.  Role of complement in tubulointerstitial injury from proteinuria.

Authors:  Sydney Tang; Kar Neng Lai; Steven H Sacks
Journal:  Kidney Blood Press Res       Date:  2002       Impact factor: 2.687

Review 3.  Complement and the kidney.

Authors:  Richard J Quigg
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

4.  C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys.

Authors:  Masaomi Nangaku; Jeffrey Pippin; William G Couser
Journal:  J Am Soc Nephrol       Date:  2002-04       Impact factor: 10.121

5.  Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice.

Authors:  Lihua Bao; Mark Haas; Susan A Boackle; Damian M Kraus; Patrick N Cunningham; Pierce Park; Jessy J Alexander; Randall K Anderson; Kristin Culhane; V Michael Holers; Richard J Quigg
Journal:  J Immunol       Date:  2002-04-01       Impact factor: 5.422

6.  Local synthesis of complement component C3 regulates acute renal transplant rejection.

Authors:  Julian R Pratt; Shamim A Basheer; Steven H Sacks
Journal:  Nat Med       Date:  2002-06       Impact factor: 53.440

Review 7.  Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: a therapeutic role for complement inhibitors?

Authors:  Stephen I-Hong Hsu; William G Couser
Journal:  J Am Soc Nephrol       Date:  2003-07       Impact factor: 10.121

8.  Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial.

Authors:  Christopher B Granger; Kenneth W Mahaffey; W Douglas Weaver; Pierre Theroux; Judith S Hochman; Thomas G Filloon; Scott Rollins; Thomas G Todaro; Jose C Nicolau; Witold Ruzyllo; Paul W Armstrong
Journal:  Circulation       Date:  2003-08-18       Impact factor: 29.690

9.  Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass.

Authors:  Jennifer S Li; Stephen P Sanders; April E Perry; Sandra S Stinnett; James Jaggers; Paula Bokesch; Laurie Reynolds; Rashid Nassar; Page A W Anderson
Journal:  Am Heart J       Date:  2004-01       Impact factor: 4.749

Review 10.  Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.

Authors:  Mark J Sarnak; Andrew S Levey; Anton C Schoolwerth; Josef Coresh; Bruce Culleton; L Lee Hamm; Peter A McCullough; Bertram L Kasiske; Ellie Kelepouris; Michael J Klag; Patrick Parfrey; Marc Pfeffer; Leopoldo Raij; David J Spinosa; Peter W Wilson
Journal:  Circulation       Date:  2003-10-28       Impact factor: 29.690

View more
  25 in total

1.  Factor h and properdin recognize different epitopes on renal tubular epithelial heparan sulfate.

Authors:  Azadeh Zaferani; Romain R Vivès; Pieter van der Pol; Gerjan J Navis; Mohamed R Daha; Cees van Kooten; Hugues Lortat-Jacob; Marc A Seelen; Jacob van den Born
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

2.  C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria.

Authors:  Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-05-06

3.  Growth factor Midkine is involved in the pathogenesis of renal injury induced by protein overload containing endotoxin.

Authors:  Kiyonari Kato; Tomoki Kosugi; Waichi Sato; Hanayo Arata-Kawai; Takenori Ozaki; Naotake Tsuboi; Isao Ito; Hideo Tawada; Yukio Yuzawa; Seiichi Matsuo; Kenji Kadomatsu; Shoichi Maruyama
Journal:  Clin Exp Nephrol       Date:  2011-03-01       Impact factor: 2.801

4.  Intracapillary immune complexes recruit and activate slan-expressing CD16+ monocytes in human lupus nephritis.

Authors:  Florina Olaru; Thomas Döbel; Anke S Lonsdorf; Stephanie Oehrl; Michael Maas; Alexander H Enk; Marc Schmitz; Elisabeth F Gröne; Hermann-J Gröne; Knut Schäkel
Journal:  JCI Insight       Date:  2018-06-07

Review 5.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

Review 6.  Remnant nephron physiology and the progression of chronic kidney disease.

Authors:  H William Schnaper
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

7.  Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis.

Authors:  Bart Smeets; Maria Lucia Angelotti; Paola Rizzo; Henry Dijkman; Elena Lazzeri; Fieke Mooren; Lara Ballerini; Eliana Parente; Costanza Sagrinati; Benedetta Mazzinghi; Elisa Ronconi; Francesca Becherucci; Ariela Benigni; Eric Steenbergen; Laura Lasagni; Giuseppe Remuzzi; Jack Wetzels; Paola Romagnani
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

8.  Enhanced complement activation is part of the unfavourable cardiovascular risk profile in South Asians.

Authors:  M A Siezenga; P K Chandie Shaw; R N van der Geest; T E Mollnes; M R Daha; T J Rabelink; S P Berger
Journal:  Clin Exp Immunol       Date:  2009-07       Impact factor: 4.330

Review 9.  Monoclonal antibodies for podocytopathies: rationale and clinical responses.

Authors:  Maddalena Marasà; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2009-06       Impact factor: 28.314

10.  SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.

Authors:  Paola Cassis; Monica Locatelli; Domenico Cerullo; Daniela Corna; Simona Buelli; Cristina Zanchi; Sebastian Villa; Marina Morigi; Giuseppe Remuzzi; Ariela Benigni; Carlamaria Zoja
Journal:  JCI Insight       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.